Here's Why Big Pharma is Rooting for Portola

Pfizer (PFE), Bristol-Myers (BMY), Johnson & Johnson (JNJ) and Bayer (BAYRY) stand to make big money if Portola's anti-coagulant antidote succeeds.

Feb 5, 2014 at 9:38AM

Big drug makers Pfizer (NYSE:PFE), Bristol-Myers (NYSE:BMY), Johnson & Johnson (NYSE:JNJ), and Bayer (NASDAQOTH:BAYRY) are always interested in collaborating with emerging biotech companies with promising new therapies. However, their interest in Portola Pharmaceuticals (NASDAQ:PTLA) could conceivably have a much more profound effect on their bottom lines.

That's because Portola, a company that has seen its shares leap more than 75% since its IPO last year, is developing an antidote to new anti-coagulant drugs from these big pharma players. Those anti-coagulant drugs are Xarelto by Johnson & Johnson and Bayer, and Eliquis by Pfizer and Bristol-Myers Squibb.

PTLA Chart

PTLA data by YCharts

Solving a big problem
For 50 years, warfarin has been a go-to therapy for doctors trying to prevent blood clots from forming in patients following surgery or suffering from heart disease. It's a big market opportunity given that as many as 40%-60% of patients undergoing orthopaedic surgery may develop blood clots; also, atrial fibrillation, a condition for which warfarin is commonly prescribed, is on the rise.

However, warfarin's market dominance is fading as new therapies have hit the market promising less risk of hemorrhages, less monitoring, and fewer dose adjustments.

As a result, Boehringer, the maker of Pradaxa -- the market share leader of the new therapies -- is already selling a billion dollars worth of its anticoagulant. Bayer and Johnson's Xarelto sales are also at a billion dollar run rate given sales of the drug reached $271 million in the fourth quarter. Pfizer and Bristol's Eliquis is pulling up the rear, but sales have grown dramatically in the past two quarters from $12 million in Q2 to $71 million in Q4.

Those are some impressive numbers, but there's a major stumbling block holding revenue back. None have an effective counter measure capable of reversing their effect. That's a big hurdle for doctors unwilling to prescribe the drugs to patients at risk for bleeding events. It's also a big problem for treating emergency bleeding in patients that do suffer hemorrhages.

Stepping up with Portola
Bayer, Johnson, Pfizer, and Bristol all realize hundreds of millions more in sales could be captured if an effective antidote can be commercialized. As a result, the companies are funding Portola's late stage clinical trials for the company's Xa factor decoy, a drug designed to counteract the Xa factor inhibiting ability of Xarelto and Eliquis.

Following a successful collaboration in phase 2 and the FDA breakthrough designation for the decoy in November, Bayer and Johnson agreed to sign on for phase 3 trials too. Bristol and Pfizer have inked a similar arrangement for phase 3 and factor Xa inhibiting hopeful Daichi is also working with Portola.

Importantly, all those collaborations were made by big pharma despite Portola holding onto the drug's potential commercialization rights, and despite Portola's advancing its own competing anti-coagulant drug in late stage trials.

Fool-worthy final thoughts
Solving the riddle of reversing the affect of Xarelto and Eliquis substantially improves these drugs' marketability. That's likely to prove even more important given hip replacements, AF, and other conditions where anticoagulants are indicated occur more frequently as we get older.

Portola may see an additional benefit if it can show its antidote works on generic enoxaparin. Sales of enoxaparin, which was formerly sold as the brand drug Lovenox, totaled $320 million in the third quarter of 2013 and enoxaparin's current antidote, Protamine, only reverses a maximum of 60% of its effect.

Portola is a compelling growth story to watch, and some of the world's biggest pharma companies are rooting for its success. However, it's important to remember that this stock's growth ultimately hinges on successful clinical trial data.

Another company with big time potential
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Todd Campbell has no position in any stocks mentioned. Todd owns E.B.Capital Markets, LLC.  E.B. Capital Markets' clients may or may not have positions in the companies mentioned.  Todd also owns Gundalow Advisor's, LLC.  Gundalow's clients do not own shares in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information